PL2813225T3 - Sposób leczenia zatrucia związkami fosforoorganicznymi - Google Patents

Sposób leczenia zatrucia związkami fosforoorganicznymi

Info

Publication number
PL2813225T3
PL2813225T3 PL14002959T PL14002959T PL2813225T3 PL 2813225 T3 PL2813225 T3 PL 2813225T3 PL 14002959 T PL14002959 T PL 14002959T PL 14002959 T PL14002959 T PL 14002959T PL 2813225 T3 PL2813225 T3 PL 2813225T3
Authority
PL
Poland
Prior art keywords
treating
organophosphorous poisoning
poisoning
treating organophosphorous
organophosphorous
Prior art date
Application number
PL14002959T
Other languages
English (en)
Inventor
Michael Adler
Edson X. Albuquerque
Edna F. R. Pereira
Original Assignee
University Of Maryland, Baltimore
The Government Of The United States As Represented By The Secretary Of The Army U.S. Army Medical Research Institute Of Chemical Defense
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Maryland, Baltimore, The Government Of The United States As Represented By The Secretary Of The Army U.S. Army Medical Research Institute Of Chemical Defense filed Critical University Of Maryland, Baltimore
Publication of PL2813225T3 publication Critical patent/PL2813225T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14002959T 2004-09-24 2005-09-23 Sposób leczenia zatrucia związkami fosforoorganicznymi PL2813225T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61312104P 2004-09-24 2004-09-24
EP14002959.6A EP2813225B1 (en) 2004-09-24 2005-09-23 Method of treating organophosphorous poisoning
EP05812994.1A EP1791904B1 (en) 2004-09-24 2005-09-23 Method of treating organophosphorous poisoning

Publications (1)

Publication Number Publication Date
PL2813225T3 true PL2813225T3 (pl) 2018-11-30

Family

ID=36119406

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14002959T PL2813225T3 (pl) 2004-09-24 2005-09-23 Sposób leczenia zatrucia związkami fosforoorganicznymi
PL05812994T PL1791904T3 (pl) 2004-09-24 2005-09-23 Sposób leczenia zatrucia związkami fosforoorganicznymi

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL05812994T PL1791904T3 (pl) 2004-09-24 2005-09-23 Sposób leczenia zatrucia związkami fosforoorganicznymi

Country Status (10)

Country Link
US (2) US7888346B2 (pl)
EP (2) EP2813225B1 (pl)
JP (2) JP5710092B2 (pl)
CN (1) CN101044200A (pl)
AU (1) AU2005289808B2 (pl)
CA (1) CA2583439C (pl)
ES (2) ES2519690T3 (pl)
IL (2) IL182048A0 (pl)
PL (2) PL2813225T3 (pl)
WO (1) WO2006036686A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel
JP2014062084A (ja) * 2012-09-19 2014-04-10 Georgetown Univ 標的化されたリポソーム
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CN103041368B (zh) * 2013-01-18 2014-04-02 新乡医学院 藻蓝蛋白在制备防治有机磷农药所致胚胎毒性的药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292308A (en) * 1979-08-21 1981-09-29 Biotherapeutics, Inc. Treatment of animals exposed to or subject to exposure to organophosphate animal poisonous nerve agents
US4550113A (en) 1982-08-19 1985-10-29 Nauchno-Issledovatelsky Institut Po Biologicheskikm Ispytaniyam Khimicheskikh Soedineny 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles
RU2057531C1 (ru) 1986-07-01 1996-04-10 Всероссийский научный центр по безопасности биологически активных веществ Средство для стимуляции обучения и памяти
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5480651A (en) 1992-03-16 1996-01-02 Regents Of The University Of California Composition and method for treating nicotine craving in smoking cessation
DE4342173A1 (de) 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
DE4342174C1 (de) * 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
DE69735354T2 (de) 1996-10-28 2006-11-30 Amersham Health As Verbesserungen an oder in verbindung mit diagnostischen/therapeutischen verbindungen
AU9496798A (en) 1997-09-19 1999-04-05 Shire Laboratories, Inc. Solid solution beadlet
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
UA66370C2 (en) 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
US6211230B1 (en) * 1999-09-27 2001-04-03 The United States Of America As Represented By The Secretary Of The Army Method of reducing brain damage resulting from seizures
AR031078A1 (es) 1999-10-29 2003-09-10 Takeda Pharmaceutical Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.
US6617361B2 (en) 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
WO2001043697A2 (en) 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
JP2001261652A (ja) 2000-03-21 2001-09-26 Suntory Ltd 二置換イミノヘテロサイクリック化合物
WO2001085699A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6756385B2 (en) 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
IT1317908B1 (it) 2000-09-15 2003-07-15 S I S S A Scuola Internaz Supe Muteine del frammento peptidico cgrp 1-7 e loro uso come potenziatoridei recettori nicotinici neuronali.
US6589504B1 (en) 2000-09-22 2003-07-08 Pharmacia & Upjohn Company Compounds and methods for diagnosing and treating amyloid-related conditions
EP1340749A4 (en) 2000-11-17 2007-09-05 Takeda Pharmaceutical isoxazole
CN1481360A (zh) 2000-12-22 2004-03-10 ���鹫˾ 蕈毒碱拮抗剂
CA2437492A1 (en) 2001-02-02 2002-08-15 Yoshihiro Banno Fused heterocyclic compounds
AU2002253929A1 (en) 2001-02-08 2002-09-24 Schering Corporation Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
KR100437972B1 (ko) 2001-10-27 2004-07-02 한국과학기술연구원 피롤리디논 유도체, 이의 제조 방법 및 이를 포함하는제약 조성물
KR100432283B1 (ko) 2001-10-27 2004-05-22 한국과학기술연구원 무스카린성 아세틸콜린 수용체에 작용하는테트라하이드로피리딘 유도체
CA2504349A1 (en) 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid
GB0202900D0 (en) 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
US7015345B2 (en) 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
WO2003092606A2 (en) * 2002-05-01 2003-11-13 Eisai Co., Ltd. Cholinesterase inhibitors to prevent injuries caused by chemicals
CN1389462A (zh) 2002-07-12 2003-01-08 复旦大学 大叶蒟素及其同系物，和在制备药物组合物中的应用
US7045527B2 (en) 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
US20040067934A1 (en) 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
CA2503381A1 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US20050013869A1 (en) * 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor

Also Published As

Publication number Publication date
WO2006036686A3 (en) 2007-02-22
JP2013173773A (ja) 2013-09-05
AU2005289808A2 (en) 2008-07-31
WO2006036686A2 (en) 2006-04-06
US8703762B2 (en) 2014-04-22
CA2583439A1 (en) 2006-04-06
US20110144093A1 (en) 2011-06-16
IL218241A0 (en) 2012-04-30
EP2813225B1 (en) 2017-12-13
CA2583439C (en) 2016-05-10
EP1791904B1 (en) 2014-08-27
AU2005289808B2 (en) 2011-11-03
IL218241A (en) 2016-03-31
PL1791904T3 (pl) 2015-02-27
JP5710092B2 (ja) 2015-04-30
US7888346B2 (en) 2011-02-15
EP2813225A1 (en) 2014-12-17
IL182048A0 (en) 2007-07-24
EP1791904A4 (en) 2009-01-21
ES2519690T3 (es) 2014-11-07
AU2005289808A1 (en) 2006-04-06
CN101044200A (zh) 2007-09-26
ES2662868T3 (es) 2018-04-10
JP2008514609A (ja) 2008-05-08
US20080070900A1 (en) 2008-03-20
EP1791904A2 (en) 2007-06-06

Similar Documents

Publication Publication Date Title
IL180742A0 (en) Method of manufacture
EP1838714A4 (en) METHODS OF TREATING PAIN
EP1755394A4 (en) METHOD OF TREATING CANCER
IL183059A0 (en) Cancer treatment method
IL179323A0 (en) Cancer treatment method
GB0422004D0 (en) Method of deprotection
IL218241A0 (en) Method of treating organophosphorous poisoning
IL159893A0 (en) Method of terrain following
EP1737445A4 (en) METHOD FOR TREATING DOWN SYNDROME
EP1809276A4 (en) PROCESSING PROCESS
IL179359A0 (en) Cancer treatment method
EP1781322A4 (en) METHOD OF TREATING DIABETES
GB0422533D0 (en) Non-aqueous treatment method
EP1802617A4 (en) CANCER TREATMENT METHOD
EP1856733A4 (en) METHOD FOR LED MICRO PACKAGING AND MICRO PACKAGING
EP1843780A4 (en) Methods of Treatment
EP1688503A4 (en) METHOD FOR THE TREATMENT OF CELLS
GB0400122D0 (en) Method of quantifying binding
GB0408799D0 (en) Method of treating pain
GB0406103D0 (en) Treatment method
HU0402689D0 (en) Method for regeneration of zeolits
PL366960A1 (pl) Sposób modyfikacji bio-membran
GB0419826D0 (en) Method of determination
GB0514050D0 (en) Method of determination
HUP0401136A3 (en) Method for post-blinding of gas-plumbing